Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck: KEYNOTE-671 trial meets dual primary endpoint of OS
- Merck announces AMBASSADOR trial meets one of two primary endpoints of DFS
- Merck’s new application for sotatercept given priority review by FDA
- Unusually active option classes on open September 26th
- Merck, Eisai provide update on Phase 3 trials, LEAP-006 and LEAP-008